Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Promotes Sarah Romano to Chief Financial Officer

WALTHAM, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform...
December 19, 2017 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the Eye

WALTHAM, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform...
December 18, 2017 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone Payment

WALTHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform...
November 14, 2017 08:00 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 14, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
November 08, 2017 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract Surgery

WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform...
November 01, 2017 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy

WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
October 23, 2017 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

Eye Care Thought Leaders Join EyeGate Scientific Advisory Board

WALTHAM, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company focused on developing...
September 11, 2017 06:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships

WALTHAM, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company focused on developing...
September 05, 2017 06:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharma to Present at the 19th Annual Rodman and Renshaw Global Investment Conference

WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company focused on developing...
August 07, 2017 07:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right